Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in patients with TIPS

American Journal of Gastroenterology

Volumn 96, Issue 7, 2001, Pages 2218-2224

  Schiedermaier, Peter ^a   Göke, Burkhard ^b   Sauerbruch, Tilman ^a  

^a UNIVERSITY OF BONN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; OCTREOTIDE; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; DOPPLER FLOWMETRY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEMODYNAMICS; HUMAN; MALE; NON INVASIVE MEASUREMENT; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW;

BLOOD FLOW VELOCITY; FEMALE; GLUCAGON; HEMODYNAMIC PROCESSES; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PORTAL PRESSURE; PORTAL VEIN; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; SPLANCHNIC CIRCULATION; ULTRASONOGRAPHY, DOPPLER;

EID: 0034943660     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02523-0     Document Type: Article

References (37)

1. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage
2. Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding
3. Sclerotherapy with or without octreotide for acute variceal bleeding
4. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation
5. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage
6. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial
7. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: A double-blind, placebo-controlled study
8. Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis
9. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension
10. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-Doppler study
11. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis
12. Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure
13. The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients
14. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension
15. Somatostatin or octreotide in acute variceal bleeding
16. Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings
17. Role of glucagon in splanchnic hyperemia of chronic portal hypertension
18. Glucagon selectively increases splanchnic blood flow in patients with well-compensated cirrhosis
19. The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis
20. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis
21. Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in healthy volunteers
22. Hemodynamic effects of glucagon in portal hypertension
23. Somatostatin-induced contraction of human isolated saphenous vein involves sst2 receptor-mediated activation of L-type calcium channels
24. Quantitative measurement of portal blood flow in patients with chronic liver disease using an ultrasonic duplex system consisting of a pulsed Doppler flowmeter and B-mode electroscanner
25. Clinical application of an ultrasonic duplex system in the quantitative measurement of portal blood flow
26. Clinical utility of pulsed Doppler flowmetry in patients with portal hypertension
27. Prognostic significance of portal hemodynamics in patients with compensated cirrhosis
28. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices
29. Timing of the first variceal hemorrhage in cirrhotic patients: Prospective evaluation of Doppler flowmetry, endoscopy and clinical parameters
30. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
31. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis
32. Relationship between directly measured portal pressure gradient and variceal hemorrhage
33. Clinical vs haemodynamic response to drugs in portal hypertension
34. Correlation of duplex sonography findings and portal pressure in 375 patients with portal hypertension
35. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone
36. Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis
37. Doppler sonography and hepatic vein catheterization in portal hypertension: Assessment of agreement in evaluating severity and response to treatment